Calliditas Therapeutics (CALT)
(Delayed Data from NSDQ)
$40.88 USD
+0.53 (1.31%)
Updated Aug 27, 2024 03:59 PM ET
4-Sell of 5 4
F Value A Growth A Momentum B VGM
Brokerage Reports
0 items in cart
Calliditas Therapeutics AB Sponsored ADR [CALT]
Reports for Purchase
Showing records 1 - 20 ( 28 total )
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Calliditas To be Acquired at a Premium; Downgrade to Neutral; PT to Acquisition Price of $39
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Underlying Fundamentals Remain Strong; Adjust PT Down to $45; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
IgAN Market Potential Further Validated by Another Big Pharma Acquisition; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Optimized Entry and Exit Levels for CALT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Potential Transformative Approvals Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Near-Term Competition Further Alleviated; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Not All Proteinuria Reductions Are the Same; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Slower Than Expected Nefecon Growth; Lower PT to $50; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Developing Innovative Treatment for Orphan Renal and Hepatic Diseases; Initiate With Buy and a $60 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: HE A
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Thoughts Post TARPEYO Approval; Model Update; Raising PT to $62
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Nefecon, Now TARPEYO, Is Approved As the First Drug Indicated For IgAN
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Nefecon PDUFA Right Around the Corner; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
Company: Calliditas Therapeutics AB Sponsored ADR
Industry: Medical - Drugs
PDUFA Extension Is Not Thesis Changing for Nefecon
Provider: H.C. Wainwright & Co., Inc.
Analyst: ZHANG E